Perspective Life (300642) 2023 Report and 2024 Quarterly Report Review: Performance Under Pressure Due to Collection and Medical Compliance Actions
Perspective Life (300642) Review of the 2023 Third Quarter Report: Q3 revenue growth was pressured, and gross margin recovered relatively well
Perspective Life (300642): Reagent revenue grew rapidly in the second quarter, and gross margin clearly rebounded
Perspective Life (300642): The epidemic disrupts short-term performance and is expected to resume steady operations after the external environment improves this year
Perspective Life (300642): Business conditions improve quarter by quarter, all-in-one computers expand gap customers
Perspective Life (300642): Steady growth and accelerated installation of nucleic acid pretreatment systems under the turmoil of the epidemic
Tuojing Life (300642): performance under short-term pressure and looking forward to follow-up efforts
Through Jingsheng (300642): affected by the epidemic, performance is under pressure and is expected to recover in the second half of the year.
Perspective Life (300642): Marketing reforms have achieved initial results, and performance has been greatly disrupted by the epidemic in the short term
Toujing Life (300642) 2021 Annual report and 2022 Quarterly report comments: 21 years of rapid growth in the first quarter of 22 due to the epidemic pressure
Perspective Life (300642): Repeated epidemics have put pressure on short-term performance to expand COVID-19 testing supporting products, leading to an increase
Perspective Life (300642): the epidemic repeatedly affects short-term performance, and luminous installation acceleration is expected to establish medium-and long-term sustainable growth.
Perspective Life (300642) 2021 Third Quarter Report Review: Operation was under pressure in the third quarter due to the spread of the epidemic
Perspective Life (300642): Business recovery is obvious, domestic marketing reforms are beginning to bear fruit
Tuojing Life (300642): the performance is in line with the expected marketing reform and achieved remarkable results.
Tuojing Life (300642) 2021 report comments: swelling and HPV testing business recovery is good, auto-immunity testing and other new products can be released.
Tuojing Life (300642) 2021 performance Forecast Review: new products such as tumor markers and HPV testing for recovery, high growth and autoimmunity are expected to be released.
Through Jingsheng (300642) in-depth Research report: waiting for the flowers to blossom after the marketing reform
Toujing Life (300642): new products gradually expand the volume of marketing to improve performance growth
Toujing Life (300642): the performance is in line with the expected strong recovery of 21Q1.
No Data